For the first time, an mRNA cancer vaccine has succeeded in a late-stage clinical trial, a significant advance that could reshape how cancer is treated.

On Aug. 19, 2026, Moderna and Merck announced that their personalized vaccine, intismeran autogene, succeeded in reducing the recurrence of the skin cancer melanoma when combined with the immunotherapy drug Keytruda.

While these results could open the door to a wave of cancer vaccines, misinformation about mRNA technology circulating since the COVID-19 pandemic could undermine its momentum before it reaches patients.

The progress toward vaccines to treat cancer has been building for years. Since the early 2000s, there have been over 120 promising clinical trials testing the use of mRNA vaccines to treat multiple cancer types, such as melanoma, brain, breast, lung and prostate cancer.

At the same time, misinformation about so-called turbo cancer began spreading widely on social media, with mainstream media outlets first reporting on it in late 2022. Turbo cancer refers to the false claim that COVID-19 mRNA vaccines cause unusually aggressive cancers.

As a researcher in health communication who monitors cancer-related conversations online, I have seen how quickly new misinformation can spread and the impact it can have on people's health decisions.

In the case of mRNA cancer vaccines, this false narrative could undermine public confidence in an important tool that may help prevent or treat cancer in the future.

Cancer...

Read Full Story: https://news.google.com/rss/articles/CBMitAFBVV95cUxQUlhTczJORnVFVGRRVTV1ZzE0...